Compare Neurocrine Biosciences Inc (NBIX) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prudential PLC — how do they compare? Neurocrine Biosciences Inc trades at $141.27 (market cap $14.36B), while Prudential PLC trades at $23.85 (market cap $28.84B). The key difference: Prudential PLC is far larger — about 2× Neurocrine Biosciences Inc's market cap, and Prudential PLC pays a 2.33% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Prudential PLC for 119 Days on average.
| NBIX | PUK | |
|---|---|---|
Market Cap | $14.36B | $28.84B |
Volume | 1,237,180 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $185.50 | $33.61 |
52-Week Low | $123.10 | $23.54 |
Typical Hold Time | 23 Days | 119 Days |
Enterprise Value | $14.37B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
PUK trades at $23.54, down 4.31% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent news highlights strategic moves including the sale of its Alexforbes stake and a rebranding of its wealth management unit. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook is mixed: solid fundamentals and growth initiatives support upside, but technical weakness and earnings volatility pose risks. Investment opportunity lies in the attractive valuation (P/E 8.4) and strategic focus, countered by bearish momentum and competitive pressures in insurance markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
